PMID- 11526599
OWN - NLM
STAT- MEDLINE
DCOM- 20020306
LR  - 20191105
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 38
IP  - 3 Suppl 8
DP  - 2001 Jul
TI  - Implications of imatinib mesylate for hematopoietic stem cell transplantation.
PG  - 28-34
AB  - The ability of allogeneic bone marrow or blood stem cell transplantation (SCT) to 
      induce long-term remission or cure of chronic myeloid leukemia (CML) is well 
      established. However, the use of this treatment is limited by the availability of 
      suitable human leukocyte antigen (HLA) identical siblings or matched unrelated 
      donors (MUD). As a consequence only a relatively small proportion of CML patients 
      are eligible for a transplant, and of these not all are cured. The preliminary 
      results of trials using the new Bcr-Abl kinase inhibitor imatinib mesylate 
      (formerly CGP57-148B, STI571, Gleevec) to treat CML are very encouraging. 
      However, a number of important questions cannot yet be answered: Can imatinib 
      mesylate induce durable molecular remissions? Can the drug prolong survival in 
      comparison with other nontransplant treatments? and, can it actually cure CML 
      patients? Until answers to these questions are available, SCT and use of 
      interferon-alfa (IFN-alpha) alone or in combination (perhaps with imatinib 
      mesylate) must remain major therapeutic options. I summarize here the advantages 
      and disadvantages associated with currently available therapy. I review three 
      different approaches to initial treatment of the CML patient diagnosed in chronic 
      phase, and make a tentative recommendation for one of these options. It is likely 
      that the situation will alter considerably in the foreseeable future.
CI  - Copyright 2001 by W.B. Saunders Company.
FAU - Goldman, J
AU  - Goldman J
AD  - Department of Haematology, Imperial College School of Medicine, Hammersmith 
      Hospital, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Algorithms
MH  - Antineoplastic Agents/*therapeutic use
MH  - Benzamides
MH  - Enzyme Inhibitors/therapeutic use
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
MH  - Piperazines/*therapeutic use
MH  - Pyrimidines/*therapeutic use
RF  - 19
EDAT- 2001/08/30 10:00
MHDA- 2002/03/07 10:01
CRDT- 2001/08/30 10:00
PHST- 2001/08/30 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2001/08/30 10:00 [entrez]
AID - ashem0380028s8 [pii]
AID - 10.1016/s0037-1963(01)90115-5 [doi]
PST - ppublish
SO  - Semin Hematol. 2001 Jul;38(3 Suppl 8):28-34. doi: 10.1016/s0037-1963(01)90115-5.